These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26689604)

  • 21. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin.
    Garg V; Chandorkar G; Farmer HF; Smith F; Alves K; van Heeswijk RP
    J Clin Pharmacol; 2012 Oct; 52(10):1566-73. PubMed ID: 22162542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.
    Chenel M; Ogungbenro K; Duval V; Laveille C; Jochemsen R; Aarons L
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):737-56. PubMed ID: 16341474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count data.
    Loingeville F; Nguyen TT; Riviere MK; Mentré F
    J Biopharm Stat; 2020; 30(1):31-45. PubMed ID: 31032703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robust designs accounting for model uncertainty in longitudinal studies with binary outcomes.
    Seurat J; Nguyen TT; Mentré F
    Stat Methods Med Res; 2020 Mar; 29(3):934-952. PubMed ID: 31131705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam.
    Tomalik-Scharte D; Suleiman AA; Frechen S; Kraus D; Kerkweg U; Rokitta D; Di Gion P; Queckenberg C; Fuhr U
    J Clin Pharmacol; 2014 Oct; 54(10):1162-9. PubMed ID: 24782075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments.
    Graham G; Aarons L
    Stat Med; 2006 Dec; 25(23):4004-19. PubMed ID: 16463254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
    Nguyen TT; Bazzoli C; Mentré F
    Stat Med; 2012 May; 31(11-12):1043-58. PubMed ID: 21965170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
    Ryu JY; Song IS; Sunwoo YE; Shon JH; Liu KH; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2007 Nov; 82(5):531-40. PubMed ID: 17392720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.
    Retout S; Duffull S; Mentré F
    Comput Methods Programs Biomed; 2001 May; 65(2):141-51. PubMed ID: 11275334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.
    Bazzoli C; Retout S; Mentré F
    Comput Methods Programs Biomed; 2010 Apr; 98(1):55-65. PubMed ID: 19892427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimisation of sampling windows design for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2008 Aug; 35(4):465-82. PubMed ID: 18780163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal design of mixed-effects PK/PD models based on differential equations.
    Wang Y; Eskridge KM; Nadarajah S
    J Biopharm Stat; 2012; 22(1):180-205. PubMed ID: 22204534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited sampling strategy in rats to predict the inhibited activities of hepatic CYP3A.
    Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
    Lab Anim; 2009 Jul; 43(3):284-90. PubMed ID: 19237454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria.
    Tod M; Rocchisani JM
    Comput Methods Programs Biomed; 1996 Jun; 50(1):13-22. PubMed ID: 8835836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients.
    Ghassabian S; Chetty M; Tattam BN; Chem MC; Glen J; Rahme J; Stankovic Z; Ramzan I; Murray M; McLachlan AJ
    Ther Drug Monit; 2009 Apr; 31(2):239-46. PubMed ID: 19307938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
    Tham LS; Lee HS; Wang L; Yong WP; Fan L; Ong AB; Sukri N; Soo R; Lee SC; Goh BC
    Ther Drug Monit; 2006 Apr; 28(2):255-61. PubMed ID: 16628140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations.
    Fullerton T; Forrest A; Levy G
    J Pharm Sci; 1996 Jun; 85(6):600-7. PubMed ID: 8773956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.
    Salinger DH; Vicini P; Blough DK; O'Donnell PV; Pawlikowski MA; McCune JS
    J Clin Pharmacol; 2010 Nov; 50(11):1292-300. PubMed ID: 20075185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.